Literature DB >> 21670971

The role of CXCR2 chemokine receptors in the oral squamous cell carcinoma.

Juliana Romanini1, Tânia R Mielcke, Paulo C Leal, Cláudia P Figueiredo, João B Calixto, Fernanda B Morrone, Eraldo L Batista, Maria M Campos.   

Abstract

This study evaluated the relevance of CXCR2 chemokine receptors in oral squamous cell carcinoma, by means of in vitro and in vivo approaches. The in vitro incubation of the selective and non-peptide CXCR2 receptor antagonist N-(2-hydroxy-4-nitrophenyl)-N9-(2-bromophenyl) Urea (SB225002; 25 to 800 nM) produced a time- and concentration-dependent inhibition of SCC158 (rat) and HN30 (human) cell lines viability. Conversely, this antagonist did not significantly affect the viability of the immortalized keratinocyte lineage, HaCaT. Additionally, the incubation of human IL-8 and rat CINC-1 CXCR2 agonists produced a concentration-related increase on HN30 and SCC158 proliferation. The submucosal injection of SCC158 cells (5 × 10(6) cells) into the tongue of Fischer 344 rats induced tumor development, which displayed typical clinical features. Immunohistochemical analysis of rat tongue biopsies revealed a marked increase of CXCR2 receptor immunoreactivity, which was accompanied by augumented expression of VEGF and caspase-3. Our data suggests an important role for CXCR2 receptors in oral squamous cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21670971     DOI: 10.1007/s10637-011-9701-x

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  37 in total

Review 1.  ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets.

Authors:  Cinzia Bizzarri; Andrea Rosario Beccari; Riccardo Bertini; Michela Rita Cavicchia; Simona Giorgini; Marcello Allegretti
Journal:  Pharmacol Ther       Date:  2006-05-23       Impact factor: 12.310

Review 2.  The many roles of chemokines and chemokine receptors in inflammation.

Authors:  Israel F Charo; Richard M Ransohoff
Journal:  N Engl J Med       Date:  2006-02-09       Impact factor: 91.245

3.  In vitro culture conditions to study keratinocyte differentiation using the HaCaT cell line.

Authors:  Adeline F Deyrieux; V G Wilson
Journal:  Cytotechnology       Date:  2007-06-30       Impact factor: 2.058

4.  Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration.

Authors:  J R White; J M Lee; P R Young; R P Hertzberg; A J Jurewicz; M A Chaikin; K Widdowson; J J Foley; L D Martin; D E Griswold; H M Sarau
Journal:  J Biol Chem       Date:  1998-04-24       Impact factor: 5.157

5.  Bcl-2 acts in a proangiogenic signaling pathway through nuclear factor-kappaB and CXC chemokines.

Authors:  Elisabeta Karl; Kristy Warner; Benjamin Zeitlin; Tomoatsu Kaneko; Lindsey Wurtzel; Taocong Jin; Jia Chang; Shaomeng Wang; Cun-Yu Wang; Robert M Strieter; Gabriel Nunez; Peter J Polverini; Jacques E Nör
Journal:  Cancer Res       Date:  2005-06-15       Impact factor: 12.701

Review 6.  Targeting CXCR1/CXCR2 receptor antagonism in malignant melanoma.

Authors:  Bhawna Sharma; Seema Singh; Michelle L Varney; Rakesh K Singh
Journal:  Expert Opin Ther Targets       Date:  2010-04       Impact factor: 6.902

7.  Roles of CXCL8 in squamous cell carcinoma proliferation and migration.

Authors:  Emil P Christofakis; Hiroshi Miyazaki; Dustin S Rubink; W Andrew Yeudall
Journal:  Oral Oncol       Date:  2008-02-20       Impact factor: 5.337

8.  Malignancy grading of squamous cell carcinoma in the floor of the mouth related to clinical evaluation.

Authors:  G Anneroth; J G Batsakis; M Luna
Journal:  Scand J Dent Res       Date:  1986-08

Review 9.  Cancer CXC chemokine networks and tumour angiogenesis.

Authors:  Robert M Strieter; Marie D Burdick; Javier Mestas; Brigitte Gomperts; Michael P Keane; John A Belperio
Journal:  Eur J Cancer       Date:  2006-02-28       Impact factor: 9.162

10.  Clinical significance of stromal apoptosis in colorectal cancer.

Authors:  P J Koelink; C F M Sier; D W Hommes; C B H W Lamers; H W Verspaget
Journal:  Br J Cancer       Date:  2009-08-04       Impact factor: 7.640

View more
  6 in total

Review 1.  CXCR2 in acute lung injury.

Authors:  F M Konrad; J Reutershan
Journal:  Mediators Inflamm       Date:  2012-06-06       Impact factor: 4.711

2.  Expression of CXCL10 is associated with response to radiotherapy and overall survival in squamous cell carcinoma of the tongue.

Authors:  Matilda Rentoft; Philip John Coates; Lotta Loljung; Torben Wilms; Göran Laurell; Karin Nylander
Journal:  Tumour Biol       Date:  2014-01-07

3.  Increased fucosylation has a pivotal role in invasive and metastatic properties of head and neck cancer stem cells.

Authors:  Vincenzo Desiderio; Petros Papagerakis; Virginia Tirino; Li Zheng; Margarite Matossian; Mark E Prince; Francesca Paino; Luigi Mele; Federica Papaccio; Roberta Montella; Gianpaolo Papaccio; Silvana Papagerakis
Journal:  Oncotarget       Date:  2015-01-01

4.  Interleukin-1 beta transactivates epidermal growth factor receptor via the CXCL1-CXCR2 axis in oral cancer.

Authors:  Chia-Huei Lee; Shih-Han Syu; Ko-Jiunn Liu; Pei-Yi Chu; Wen-Chan Yang; Pinpin Lin; Wan-Yu Shieh
Journal:  Oncotarget       Date:  2015-11-17

5.  SB225002 Induces Cell Death and Cell Cycle Arrest in Acute Lymphoblastic Leukemia Cells through the Activation of GLIPR1.

Authors:  Jaíra Ferreira de Vasconcellos; Angelo Brunelli Albertoni Laranjeira; Paulo C Leal; Manoj K Bhasin; Priscila Pini Zenatti; Ricardo J Nunes; Rosendo A Yunes; Alexandre E Nowill; Towia A Libermann; Luiz Fernando Zerbini; José Andrés Yunes
Journal:  PLoS One       Date:  2015-08-24       Impact factor: 3.240

Review 6.  CXCL1: Gene, Promoter, Regulation of Expression, mRNA Stability, Regulation of Activity in the Intercellular Space.

Authors:  Jan Korbecki; Katarzyna Barczak; Izabela Gutowska; Dariusz Chlubek; Irena Baranowska-Bosiacka
Journal:  Int J Mol Sci       Date:  2022-01-12       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.